Recently, three human primary immunodeficiencies associated with impaired TLR signalling were described. Anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), either X-linked recessive or autosomal dominant, is caused by hypomorphic mutations in NEMO or hypermorphic mutation in IKBA, respectively, both involved in nuclear factor-κB (NF-κB) activation. These patients present with abnormal development of ectoderm-derived structures and suffer from a broad spectrum of infectious diseases. In vitro studies of the patients' cells showed an impaired, but not abolished, NF-κB activation in response to a large set of stimuli, including TLR agonists. More recently, patients with autosomal recessive amorphic mutations in IRAK4 have been reported, presenting no developmental defect and a more restricted spectrum of infectious diseases, mostly caused by pyogenic encapsulated bacteria, principally, but not exclusively Gram-positive. In vitro studies carried out with these patients' cells showed a specific impairment of the Toll-interleukin-1 receptor (TIR)-interleukin-1 receptor associated kinase (IRAK) signalling pathway. NF-κB-and mitogen activated protein kinase (MAPK) pathways are impaired in response to all TIR agonists tested. These data, therefore, suggest that TLRs play a critical role in host defence against pyogenic bacteria, but may be dispensable or redundant for immunity to most other infectious agents in humans.
INTRODUCTION
In Drosophila, Toll-dependent signalling is critical for protective immunity against numerous fungi and bacteria. 1 In the mouse, the critical role of Toll-like receptors (TLRs) in sensing microbial products has been shown first by the identification of the Lps locus, encoding TLR-4, a key component of the receptor for the Gramnegative bacterial cell wall component lipopolysaccharide (LPS). TLR-4 deficient mice were shown to be resistant to LPS-mediated shock, while they were vulnerable to Gram-negative bacteria in certain experimental conditions. 2, 3 To date, ten TLRs have been identified in mice and humans that, individually or in combination, recognize specifically their agonists. These agonists include tri-acetylated bacterial lipopeptides recognized by TLR-1/TLR-2, di-acetylated bacterial lipopeptides recognized by TLR-2/TLR-6, peptidoglycan and lipoteichoic acid recognized by TLR-2, double-stranded RNA recognized by TLR-3, LPS recognized by TLR-4, flagellin recognized by TLR-5, imidaquizoline and single-stranded RNA recognized by TLR-7 and TLR-8 (in humans), and CpG-containing DNA recognized by TLR-9. 4, 5 Agonists for TLR-10 or TLR-11 (in mice) have not been identified yet. TLRs are mostly expressed by myeloid leukocytes (phagocytes and dendritic cells) and a few lymphoid cells. Except TLRs 3, 7, 8 and 9, typically located in endosomes, the other receptors are expressed at the cell surface.
TLRs share with members of the IL-1 receptor (IL-1R) family an intracellular domain called the Toll-interleukin-1 receptor (TIR) domain. 6 Triggering of these receptors leads to the activation of the classical proinflammatory TIR signalling pathway, involving the key TIR-containing cytosolic adapter molecule MyD88, but also TIRAP (only associated with TLR-2 and TLR-4), and results in the activation of nuclear factor-κB (NF-κB) and mitogen activated protein kinases (MAPKs), via the interleukin-1 receptor-associated kinase (IRAK) complex. This classical pathway ultimately leads to the synthesis of pro-inflammatory cytokines and chemokines, such as IL-1β, IL-6, IL-8, IL-12 and TNF-α. The alternative pathway, triggered by TLRs 3, 4, 7, 8 and 9, leads to the induction of interferon (IFN)-α/β. 5, 7 The induction of IFN-α/β by TLRs 7, 8, and 9 is still poorly described. Downstream of TLR-3 and TLR-4, the alternative pathway includes the key TIR-containing adapter TRIF, but also TRAM, only associated with TLR-4. 7 The alternative pathway results in the delayed activation of NF-κB and in the rapid activation of IRF-3 via the two kinases, IKK-ε and TBK-1, leading to the synthesis of IFN-β, which induces IFN-α, thereby activating a number of target genes involved in anti-viral responses.
'Forward' genetics carried out in the mouse model first established the critical role of TLRs in host defence. 8 However, contrasting results were obtained in different knockout mouse models challenged with various pathogens (reviewed by Netea et al. 9 and Qureshi and Medzhitov 10 ). In addition, individual TLR-deficient mice showed a relatively modest susceptibility to infection. Altogether, these data suggested a redundant effect between TLRs in protective immunity in the mouse. It is also important to evaluate the biological role of human TLRs, as infection and immunity occur in natural conditions, the hallmark of the human model. 11 We will thus briefly review three Mendelian primary immunodeficiencies associated with impaired TLR signalling.
RESULTS AND DISCUSSION

Anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID)
To date, 36 patients with X-linked recessive XR-EDA-ID (reviewed by Ku et al. 12 ), and two patients with autosomal dominant AD-EDA-ID 13, 14 have been reported worldwide. EDA-ID is characterized by impaired development of ectodermal-derived structures 15, 16 and impaired host defence. Their infectious phenotype is characterised mostly by infections by encapsulated pyogenic bacteria, such as Haemophilus influenzae and Streptococcus pneumoniae, or Staphylococcus aureus that affect peripheral tissues (skin, respiratory and digestive tracts, draining lymph nodes) but also can reach deep-seated organs (liver, spleen, bones and joints) via the blood stream. Infections caused by Mycobacterium avium are also often observed. Viral infectious diseases, caused by herpes simplex virus and cytomegalovirus, and fungal diseases, such as Pneumocystis carinii pneumonitis were also diagnosed ( Table 1 ). During infections, these patients usually display poor or delayed clinical and biological inflammatory responses. 17 XR-EDA-ID is caused by hypomorphic mutations in NEMO (reviewed by Ku et al. 12 and Puel et al. 18 ). NF-κB essential modulator (NEMO or IKKγ) is the regulatory subunit of the inhibitor of NF-κB (IκB) kinase (IKK) complex, also comprising two catalytic subunits (IKKα and IKKβ), downstream of the TLRs, and a wide range of receptors involved in innate or adaptive immune responses ( Fig. 1) . 19 There is a large allelic variability, and a broad spectrum of clinical manifestations of XR-EDA-ID. 12, 20, 21 However, most but not all patients reported so far display a persistent lack of serum antibodies to carbohydrates, probably accounting for the high rate of invasive pneumococcal diseases. 17, 18, 22 Some patients have a hyper IgM syndrome and impaired CD40-mediated signalling, 23 which may account for the occurrence of Pneumocystis pneumonitis 24, 25 and some patients have NK anomalies, which may contribute to their susceptibility to herpes viruses. 20, 26 In vitro studies revealed a poor cytokine response to LPS, IL-1β and TNF-α. 24 More recently, patients with AD-EDA-ID were described, due to a hypermorphic mutation in their IKBA gene, encoding the inhibitory protein IκBα. 13, 14 The missense mutation affects one of the two phosphoacceptor serine residues on IκBα, thereby preventing its phosphorylation, ubiquitination and degradation, resulting in impaired NF-κB activation to various stimuli (Fig. 1) . In contrast to most of the XR-EDA-ID reported patients, these patients present in addition an extremely severe Tcell phenotype, with no memory T cells and an impaired T-cell response in vitro to both antigenic and CD3 mitogenic stimuli. However, a patient with a mutation in NEMO and a similar T cell phenotype was recently reported. 27 EDA-ID patients were the first human patients to present impaired TLR signalling. Nevertheless, due to the large variability of the clinical manifestations in EDA-ID patients and the complexity of the intracellular signalling pathways involved, it will be difficult to clarify the pathogenesis of infections.
IRAK-4 deficiency
Three unrelated patients from Saudi Arabia, Portugal and the US with inherited autosomal recessive IRAK-4 deficiency were recently reported. 28 Subsequently, a fourth patient from the US was identified. 29 Other patients were identified since: two Turkish siblings living in Germany, 30 three related Spaniards living in the Canaries (C. Rodríguez-Gallego and J.L. Casanova, unpublished data), a Hungarian child, an English lady 31 and two Canadian siblings 32 (D. Speert, personal communication) and reviewed by Ku et al. 12 ). To date, 12 patients with genetically proven IRAK-4 deficiency and one other with probable IRAK-4 deficiency have been identified. These patients originate from nine unrelated families and are homozygous (7 families) or compound heterozygous (2 families) for IRAK4 mutations.
IRAK-4 is a crucial kinase downstream of TLRs and IL-1Rs and upstream of TRAF-6. Blood cells from patients with IRAK-4 deficiency thus fail to produce IL-1β, IL-6, IL-8, IL-12, TNF-α, or IFN-γ in response to IL-1β, IL-18, or known TLR agonists, while their response to TNF-α is normal. 22 Their fibroblasts fail to activate both the NF-κB and MAPK (p38, ERK1/2, JNK1/2) pathways after IL-1β stimulation (Fig. 1 ). 22 Surprisingly, despite the impairment of the TLR and the 222 Puel, Yang, Ku et al. 12, 18 This suggests that IRAK-4-dependent NF-κB signalling is important for protection against pyogenic bacteria, but dispensable for immunity to most other infectious agents. Several hypotheses concerning the 'restricted' effect of IRAK-4 deficiency in human can be raised. It may be possible that a residual production of some cytokines/chemokines (other than IL-1β, IL-6, IL-8, IL-12, IFN-γ and TNF-α), independently of IRAK-4, may account for the resistance to other infections and/or inflammatory response, that can be observed at late stages of infection. In addition, the impact of IRAK-4 deficiency on the induction of IFN-α/β has not been evaluated in humans. Our preliminary data suggest that IRAK-4 deficiency blocks the induction of IFN-α/β in response to most, but not all, TLRs. Second, the impact of IRAK-4 deficiency may vary from cell to cell (only blood cells and fibroblasts were tested in the IRAK-4 deficient patients). Third, while IRAK-4 deficient patients showed apparently normal T-and B-cell responses, 28, 29 few patients seem to have a poor antibody response to carbohydrates, 22, 33 suggesting that T-independent B-cell responses might be affected.
CONCLUSIONS
Mutations in NEMO and IKBA are associated with a broad spectrum of infectious diseases, with an important clinical variability between patients. Due to the large impact of such mutations on various signalling pathways, it is still difficult to define the mechanisms involved in the pathogenesis of infections. Inherited IRAK-4 deficiency provided the first evidence that the human TIR signalling pathway plays a critical role in protective immunity. However, the critical role played by each individual family of receptors (TLRs, IL-1Rs, or other still unknown receptors) in host defence remains unknown. Indeed, it is possible that the infectious phenotype observed in IRAK-4-deficient patients results principally from impaired signalling by one or a number of members of the same receptor family. TLRs may be redundant with other sensors for protective immunity against most microbes. Mutations in individual TLRs, IL-1Rs or in a TLR/IL-1R-specific adaptor molecule or kinase would provide concrete evidence of their crucial role in human host defence. The identification of new patients with mutations in other genes involved in the TIR signalling pathway should help to elucidate the respective functions of TLRs and IL-1Rs in human protective immunity.
